PMC:7558914 / 20370-20581
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
482 | 132-144 | Gene | denotes | interferon-β | Gene:3456 |
491 | 25-36 | Chemical | denotes | oseltamivir | MESH:D053139 |
492 | 38-48 | Chemical | denotes | umifenovir | MESH:C086979 |
493 | 50-61 | Chemical | denotes | favipiravir | MESH:C462182 |
494 | 66-75 | Chemical | denotes | ribavirin | MESH:D012254 |
495 | 116-131 | Chemical | denotes | interferon-α or | |
498 | 198-206 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T132 | 0-211 | Sentence | denotes | Antiviral agents such as oseltamivir, umifenovir, favipiravir, or ribavirin as well as miscellaneous agents such as interferon-α or interferon-β are being studied for use as possible treatments for COVID-19 [3]. |